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overlapping stents, which has been associated with higher
incidence of cardiovascular events.1 The current availability
of long drug eluting stentsizes has enabled treatment of such
lesions with one, or at least fewer stents e reducing cost and
areas of stent overlap. However, longer lesion and stent length
continues to be associated with higher risk for both stent
thrombosis2,3 and in-stent restenosis.4e7 Stolker et al8 re-
ported that among patients receiving sirolimus- and
paclitaxel-eluting stents, longer stent length was associated
with higher risk for target lesion revascularization (TLR)
within one year. Naidu et al7 examined 8061 patients who
received an everolimus-eluting stent in the Xience V trial and
found that total stent length was independently associated
with stent thrombosis. Nevertheless, interventionalists often
need to stent long vessel segments, for example in patients
with diffuse disease and those with total occlusions.9
In this issue of the Journal Bahuleyan et al report outcomes
on 100 patients who underwent stenting of long coronary le-
sions (mean lesion length 24.7 ± 4.9 mm) with the Resolute™
zotarolimus eluting stent (R-ZES) in an Indian patient popu-
lation. The one-year incidence of clinically-driven TLR, target
lesion failure (TLF), and stent thrombosis was exceedingly low
at 4.5%, 6.4%, and 0%, respectively. These excellent results are
in line with the pooled analysis of the RESOLUTE Global
Clinical Trial Program, in which total lesion length was not a
predictor of TLR after R-ZES implantation.10
The R-ZES has been evaluated in over 7000 patients in the
RESOLUTE Global Clinical Trial Program.11e19 The RESOLUTE
38mmstudy enrolled 223 patientsworldwide (with the largest
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who underwent treatment with at least one 38 mm length R-
ZES.11 Baseline mean lesion length was 25.2 ± 8.8 mm and at
one year, the incidence of clinically-driven TLR, TLF, and def-
inite/probable stent thrombosis was 1.4%, 5.4%, and 0.9%,
respectively.11 Furthermore, one-year outcomes in these trials
were excellent among patients with diabetes mellitus (the
incidence of clinically-driven TLR, TLF, and definite/probable
stent thrombosis was 2.4% 6.0%, and 0%, respectively) and
similar to outcomes among non-diabetic patients.11 The
RESOLUTE Asia 38 mm cohort enrolled 109 patients (136 le-
sions) with overall mean lesion length of 26.3 ± 8.5 mm, and
lesion length among lesions treated with R-ZES of
29.1 ± 6.5 mm19 The two-year incidence of TLR, TLF, and def-
inite/probable stent thrombosis were 1.9%, 4.6%, and 0.9%,
respectively.19 Furthermore, in an analysis of the RESOLUTE
Global Clinical Program, patients with overlapping stents (644
patients with 1044 lesions and mean lesion length
22.9 ± 15.1 mm) had similar two-year clinical outcomes with
patients who did not require overlapping stents (4486 patients
with 5814 lesions andmean lesion length 14.5± 7.5mm).20 Five
year follow-up in the RESOLUTE Global Clinical Trial Program
demonstrate sustained low cardiovascular event rates.21
One possible reason why implantation with R-ZES for long
lesions was not associated with increased risk of TLR may be
the sinusoidal stent design that provides excellent conform-
ability, which is particularly important at the stent edges
where stresson the lumenwall fromthestent canbestrongest.
In contrast, other stents are typically laser cut froma tube. The
PREDICTION Study used 3D coronary reconstruction by angi-
ography/intravascular ultrasound to calculate localluate safety and Efficacy of Zotarolimus Eluting Stent (PSEZES) in
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coronary syndrome and found ZES to be associated with the
least stent edge restenosis as compared with laser cut tube
design sirolimus-eluting, paclitaxel-eluting, and bare metal
stents.22
In summary, the data presented by Bahuleyan et al and the
RESOLUTE Clinical Trial Program data suggest that R-ZES is an
excellent choice for the treatment of long coronary lesions.
The 38 mm length R-ZES allows for the treatment of longer
lesions with a single stent with outcomes similar to those
observed in shorter lesions. The currently available Resolute
Integrity ZES improves upon R-ZES by providing continuous
sinusoidal technology for further enhanced deliverability and
conformability. Themost recently developed Resolute Onyx™
ZES, which received CE Mark at the end of 2014 and is
currently under regulatory review in India, improves upon
CoreWire Technology of RI-ZES, providing thinner stent struts
and enhanced radiopacity with continued use of the clinically
proven R-ZES Biolinx™ coating.Conflicts of interest
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